S
Steven Blotner
Researcher at Genentech
Publications - 5
Citations - 389
Steven Blotner is an academic researcher from Genentech. The author has contributed to research in topics: Trastuzumab & Trastuzumab emtansine. The author has an hindex of 3, co-authored 5 publications receiving 190 citations.
Papers
More filters
Journal ArticleDOI
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Funda Meric-Bernstam,Herbert Hurwitz,Kanwal Pratap Singh Raghav,Robert R. McWilliams,Marwan Fakih,Ari M. Vanderwalde,Charles Swanton,Razelle Kurzrock,Howard A. Burris,Christopher Sweeney,Ron Bose,David R. Spigel,Mary Beattie,Steven Blotner,Alyssa Stone,Katja Schulze,Vaikunth Cuchelkar,John D. Hainsworth +17 more
TL;DR: Dual HER2-targeted therapy with pertuzumab plus trastuzumAB is well tolerated and could represent a therapeutic opportunity for patients with heavily pretreated, Her2-amplified metastatic colorectal cancer.
Journal ArticleDOI
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Razelle Kurzrock,Daniel W. Bowles,Hyunseok Kang,Funda Meric-Bernstam,John D. Hainsworth,David R. Spigel,Ron Bose,H. A. Burris,Christopher Sweeney,Michael S. Beattie,Steven Blotner,Katja Schulze,Vaikunth Cuchelkar,Charles Swanton +13 more
TL;DR: It is suggested that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination and the clinical benefit rate was 67% and the median progression-free survival was 8.6 months.
Journal ArticleDOI
Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Andreas Schneeweiss,Sibylle Loibl,Eleftherios P. Mamounas,Gunter von Minckwitz,Max S. Mano,Michael Untch,Chiun-Sheng Huang,Priya Rastogi,Pierfranco Conte,Véronique D'Hondt,Andrés Redondo,Ljiljana Stamatovic,Hervé Bonnefoi,Hugo Raul Castro Salguero,Hans Holger Fischer,Tanya A. Wahl,Chunyan Song,Steven Blotner,Peter Trask,Charles E. Geyer +19 more
TL;DR: The phase 3 KATHERINE (NCT01772472) study met its primary endpoint by demonstrating significantly improved invasive disease-free survival with adjuvant T-DM1 compared to H in pts wi...
Journal Article
Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD: End of Study Results
Proceedings ArticleDOI
Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
Max S. Mano,Sibylle Loibl,Eleftherios P. Mamounas,Gunter von Minckwitz,Chiun-Sheng Huang,Michael Untch,Norman Wolmark,Irene Wapnir,Youngsen Yang,Alison Conlin,Sherko Kümmel,Mahasti Saghatchian,Michael P. DiGiovanna,Claudia Strunk,Martina Zimovjanova,Chunyan Song,Haying Liu,D. Tesarowski,Steven Blotner,Lisa H. Lam,Melanie Smitt,Charles E. Geyer +21 more
TL;DR: Benefit was observed with T-DM1 regardless of neoadjuvant AC use and the all-grade incidence of selected AEs including hepatotoxicity, peripheral neuropathy, hemorrhage, IRR/hypersensitivity, and cardiac dysfunction was similar between non-AC and AC NACT groups.